A Potential New Therapeutic Approach for Friedreich Ataxia: Induction of Frataxin Expression With TALE Proteins

被引：22

作者：

Chapdelaine, Pierre ^{[1
,2
]}

Coulombe, Zoe ^{[1
,2
]}

Chikh, Amina ^{[1
,2
]}

Gerard, Catherine ^{[1
,2
]}

Tremblay, Jacques P. ^{[1
,2
]}

机构：

[1] Ctr Hosp Univ Quebec, Ctr Rech, Quebec City, PQ, Canada

[2] Univ Laval, Fac Med, Dept Mol Med, Quebec City, PQ G1K 7P4, Canada

来源：

MOLECULAR THERAPY-NUCLEIC ACIDS | 2013年 / 2卷

关键词：

Friedreich ataxia; frataxin; gene expression; TAL effector; transcription factor; EFFICIENT CONSTRUCTION; TRANSCRIPTION; GENE; EFFECTORS; MOUSE; IRON; TRANSDUCTION; PATHOGENESIS; DELIVERY;

D O I：

10.1038/mtna.2013.41

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

TALEs targeting a promoter sequence and fused with a transcription activation domain (TAD) may be used to specifically induce the expression of a gene as a potential treatment for haploinsufficiency. This potential therapeutic approach was applied to increase the expression of frataxin in fibroblasts of Friedreich ataxia (FRDA) patients. FRDA fibroblast cells were nucleofected with a pCR3.1 expression vector coding for TALE(Frat#8) fused with VP64. A twofold increase of the frataxin mRNA (detected by quantitative reverse transcription-PCR (qRT-PCR)) associated with a similar increase of the mature form of the frataxin protein was observed. The frataxin mRNA and protein were also increased by this TALE in the fibroblasts of the YG8R mouse model. The addition of 5-aza-2'-deoxycytidine (5-Aza-dC) or of valproic acid (VPA) to the TALE treatment did not produce significant improvement. Other TADs (i.e., p65, TFAP2 alpha, SRF, SP1, and MyoD) fused with the TALE(Frat#8) gene did not produce a significant increase in the frataxin protein. Thus the TALE(Frat#8)-VP64 recombinant protein targeting the frataxin promoter could eventually be used to increase the frataxin expression and alleviate the FRDA symptoms.

引用

页数：9

共 43 条

[1] The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues [J].

Al-Mahdawi, Sahar ;

Pinto, Ricardo Mouro ;

Ismail, Ozama ;

Varshney, Dhaval ;

Lymperi, Stefania ;

Sandi, Chiranjeevi ;

Trabzuni, Daniah ;

Pook, Mark .

HUMAN MOLECULAR GENETICS, 2008, 17 (05) :735-746

[2] GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology [J].

Al-Mahdawi, Sahar ;

Pinto, Ricardo Mouro ;

Varshney, Dhaval ;

Lawrence, Lorraine ;

Lowrie, Margaret B. ;

Hughes, Sian ;

Webster, Zoe ;

Blake, Julian ;

Cooper, J. Mark ;

King, Rosalind ;

Pook, Mark A. .

GENOMICS, 2006, 88 (05) :580-590

[3] Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments [J].

Babady, Ngolela E. ;

Carelle, Nadege ;

Wells, Robert D. ;

Rouault, Tracey A. ;

Hirano, Michio ;

Lynch, David R. ;

Delatycki, Martin B. ;

Wilson, Robert B. ;

Isaya, Grazia ;

Puccio, Helene .

MOLECULAR GENETICS AND METABOLISM, 2007, 92 (1-2) :23-35

[4] Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia [J].

Becker, E ;

Richardson, DR .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2001, 33 (01) :1-10

[5] Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors [J].

Beltran, A. ;

Parikh, S. ;

Liu, Y. ;

Cuevas, B. D. ;

Johnson, G. L. ;

Futscher, B. W. ;

Blancafort, P. .

ONCOGENE, 2007, 26 (19) :2791-2798

[6] Reprogramming epigenetic silencing:: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor [J].

Beltran, Adriana S. ;

Sun, Xueguang ;

Lizard, Paul M. ;

Blancafort, Pilar .

MOLECULAR CANCER THERAPEUTICS, 2008, 7 (05) :1080-1090

[7] Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors [J].

Boch, Jens ;

Scholze, Heidi ;

Schornack, Sebastian ;

Landgraf, Angelika ;

Hahn, Simone ;

Kay, Sabine ;

Lahaye, Thomas ;

Nickstadt, Anja ;

Bonas, Ulla .

SCIENCE, 2009, 326 (5959) :1509-1512

[8] Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers [J].

Bultmann, Sebastian ;

Morbitzer, Robert ;

Schmidt, Christine S. ;

Thanisch, Katharina ;

Spada, Fabio ;

Elsaesser, Janett ;

Lahaye, Thomas ;

Leonhardt, Heinrich .

NUCLEIC ACIDS RESEARCH, 2012, 40 (12) :5368-5377

[9] Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion [J].

Campuzano, V ;

Montermini, L ;

Molto, MD ;

Pianese, L ;

Cossee, M ;

Cavalcanti, F ;

Monros, E ;

Rodius, F ;

Duclos, F ;

Monticelli, A ;

Zara, F ;

Canizares, J ;

Koutnikova, H ;

Bidichandani, SI ;

Gellera, C ;

Brice, A ;

Trouillas, P ;

DeMichele, G ;

Filla, A ;

DeFrutos, R ;

Palau, F ;

Patel, PI ;

DiDonato, S ;

Mandel, JL ;

Cocozza, S ;

Koenig, M ;

Pandolfo, M .

SCIENCE, 1996, 271 (5254) :1423-1427

[10] Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting [J].

Cermak, Tomas ;

Doyle, Erin L. ;

Christian, Michelle ;

Wang, Li ;

Zhang, Yong ;

Schmidt, Clarice ;

Baller, Joshua A. ;

Somia, Nikunj V. ;

Bogdanove, Adam J. ;

Voytas, Daniel F. .

NUCLEIC ACIDS RESEARCH, 2011, 39 (12) :e82

← 1 2 3 4 5 →